OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
644658

6446.TW

Biotechnology & Medical ResearchVerified

The company maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 6.2, suggesting a robust ability to meet short-term obligations. The company's free cash flow of 3,153,891,000 TWD supports its operational flexibility and potential for reinvestment or shareholder returns. Profitability metrics show a return on equity of 15.78% and a return on assets of 13.49%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing at or above the industry median in terms of profitability and returns. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of -1,923,704,000 TWD indicates a reduction in investment in physical assets, which may reflect a strategic shift or a focus on optimizing existing resources. The company faces a medium liquidity risk, as noted in its risk assessment, and a low dilution risk, suggesting that the company is not expected to issue additional shares in the near term. The risk assessment also highlights that the company has a negative net cash position after accounting for total debt, which could impact its financial flexibility. Recent events, as reflected in the company's financial filings, indicate a stable financial position with no major adverse events reported in the latest period. The company's financial health is supported by strong operating cash flow and a solid equity base.

30-day price · 6446+202.00 (+30.6%)
Low$578.00High$916.00Close$862.00As of28 May, 00:00 UTC
Profile
Company6446.TW
Ticker6446.TW
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotech products and services.

Classification. The company is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

The company maintains a strong capital structure with a debt-to-equity ratio of 0.03, indicating a low reliance on debt financing. Its liquidity position is characterized by a current ratio of 6.2, suggesting a robust ability to meet short-term obligations. The company's free cash flow of 3,153,891,000 TWD supports its operational flexibility and potential for reinvestment or shareholder returns. Profitability metrics show a return on equity of 15.78% and a return on assets of 13.49%, both of which are strong indicators of efficient asset utilization and profitability. These figures are in line with the industry's preferred metrics, suggesting the company is performing at or above the industry median in terms of profitability and returns. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of -1,923,704,000 TWD indicates a reduction in investment in physical assets, which may reflect a strategic shift or a focus on optimizing existing resources. The company faces a medium liquidity risk, as noted in its risk assessment, and a low dilution risk, suggesting that the company is not expected to issue additional shares in the near term. The risk assessment also highlights that the company has a negative net cash position after accounting for total debt, which could impact its financial flexibility. Recent events, as reflected in the company's financial filings, indicate a stable financial position with no major adverse events reported in the latest period. The company's financial health is supported by strong operating cash flow and a solid equity base.
Key takeaways
  • The company has a strong capital structure with a low debt-to-equity ratio and a high current ratio.
  • Profitability metrics are robust, with a return on equity and return on assets that are in line with industry standards.
  • The company's revenue is concentrated in a single segment, which may increase its exposure to market-specific risks.
  • The company is projected to maintain a stable growth trajectory with no significant changes in revenue expected in the next fiscal year.
  • The company faces a medium liquidity risk and a low dilution risk, indicating a stable financial position.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable, supported by its strong operating income and net income.
  • **rd_outlook_rationale**: The company's research and development outlook is not explicitly provided, but its capital expenditure suggests a focus on optimizing existing resources.
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$15.63B
Gross profit$13.95B
Operating income$4.93B
Net income$5.05B
R&D
SG&A
D&A
SBC
Operating cash flow$5.28B
CapEx-$1.92B
Free cash flow$3.15B
Total assets$37.41B
Total liabilities$5.44B
Total equity$31.98B
Cash & equivalents
Long-term debt$856.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$31.98B
Net cash-$856.0M
Current ratio6.2
Debt/Equity0.0
ROA13.5%
ROE15.8%
Cash conversion1.1%
CapEx/Revenue-12.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
Metric6446Activity
Op margin31.5%2.4% medp25 -91.8% · p75 12.5%top quartile
Net margin32.3%1.2% medp25 -98.4% · p75 10.4%top quartile
Gross margin89.2%45.6% medp25 29.8% · p75 66.7%top quartile
CapEx / revenue-12.3%-5.2% medp25 -15.8% · p75 -1.7%below median
Debt / equity3.0%9.3% medp25 0.1% · p75 43.8%below median
Observations
IR observations
Mean price target774.86 TWD
Median price target820.00 TWD
High price target1,090.00 TWD
Low price target550.00 TWD
Mean recommendation1.90 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count5.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate22.96 TWD
Last actual EPS13.59 TWD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 11:14 UTC#d8ac6074
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 01:38 UTCJob: 60451663